- About us
- Clinical trials
- News & Publications
ASCO 2021 DCVAC OvCa SOV01 biomarker analyses
WE WANT TO HAVE A SAY IN THINGS
“Out of the approximately 400 programs we analyze annually, only one or two result in a successfully completed transaction,” says Radek Špíšek, CEO of the biotechnology company Sotio.
Three years ago, Radek Špíšek said that he had a hard time falling asleep, knowing how much money Petr Kellner spends on Sotio. Kellner, the wealthiest Czech and the founder of the PPF business empire, established the biotechnology company 10 years ago, aiming to eventually develop a proprietary cancer treatment. The person to do that was to be none other than Radek Špíšek, who was at that time working as an immunotherapy specialist in the Motol Hospital. His bad dreams are now over. Shortly before the end of last year, Sotio managed to close a highly profitable deal, albeit in the investment field. “Our biggest dream still is that Sotio will become a pharmaceutical company,” stresses Špíšek.
ROULETTE OF LIFE
BEING RICH AND HEALTHY IS BETTER THAN BEING POOR AND ILL. BEING HEALTHY AND GETTING RICH ON OTHERS’ HEALTH IS BEST. THE BUSINESS OF DEVELOPING AND MARKETING DRUGS IS A DRAMATIC AND VERY COSTLY ADVENTURE WITH A TINY CHANCE OF SUCCESS, AND NOT JUST DURING THE CORONAVIRUS ERA. STILL, IT IS ONLY LOGICAL THAT PETR KELLNER AND KAREL KOMÁREK ARE INVOLVED IN IT.